(RTTNews) - AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan or Dato-DXd compared to the investigator's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback